GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Glenmark Pharmaceuticals Ltd
Glenmark Pharma Board to Approve Q2 & H1 FY27 Unaudited Financial Results
RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 23 Oct 2026, 11:44 AM IST  ·  BSE ID: 33582a66-f4b0-453a-b361-5418aab48f26
View Original BSE Filing (PDF)
💡
In Simple Terms
Glenmark Pharma's board will meet on November 5, 2026, to approve its financial results for the quarter and half-year.
🤖 AI Summary
  • Glenmark Pharmaceuticals Board meeting scheduled for Thursday, November 5, 2026.
  • Purpose: To consider and approve Unaudited Financial Results for Q2 and half year ended September 30, 2026.
  • Results will cover both Standalone and Consolidated financial statements.
  • Trading window for designated persons closed October 1, 2026, to reopen November 8, 2026.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any action based on this intimation.
👤
Who Is Affected
Designated persons, including Directors, Key Managerial Personnel, Identified Employees, and their immediate relatives, are currently restricted from trading in Glenmark Pharmaceuticals securities until November 7, 2026.
🔍
Management Signal
Management is adhering to regulatory timelines by scheduling the board meeting for financial results approval and implementing the trading window closure.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Unaudited Financial Results announcement on November 5, 2026.
Review of Q2 and H1 FY27 consolidated revenue and profit figures.
Analysis of management commentary following the results disclosure.
LOW RISK This is a routine regulatory disclosure with no new inherent risks identified.
💡 Investor Takeaway
Glenmark Pharmaceuticals has scheduled a Board Meeting for November 5, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026. The trading window for designated persons remains closed until November 7, 2026.
📅 Company Track Record
Glenmark Pharmaceuticals reported consolidated revenue up 23.1% YoY to Rs. 40,185 million for Q1 FY27, as per their July 31, 2026 filing. The upcoming results will provide an update on the financial performance trend.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is Glenmark Pharmaceuticals' Board Meeting scheduled?
Glenmark Pharmaceuticals' Board Meeting is scheduled for Thursday, November 5, 2026.
What is the purpose of the upcoming Board Meeting for Glenmark Pharmaceuticals?
The Board Meeting is scheduled to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half year ended September 30, 2026.
When does the trading window for Glenmark Pharmaceuticals reopen for designated persons?
The trading window for designated persons of Glenmark Pharmaceuticals, which closed on October 01, 2026, will reopen on Sunday, November 08, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.